U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.

Cover of Medical Genetics Summaries

Medical Genetics Summaries [Internet].

Show details

Risperidone Therapy and CYP2D6 Genotype

, MD.

Author Information and Affiliations

Created: .

Estimated reading time: 13 minutes


Risperidone is the most commonly prescribed antipsychotic medication in the US. It is an atypical (second generation) antipsychotic used in the treatment of schizophrenia, bipolar disorder, severe dementia, and irritability associated with autism.

Risperidone is metabolized to the active metabolite 9-hydroxyrisperidone by the enzyme CYP2D6 and to a lesser extent by CYP3A4. Individuals who carry two inactive copies of the CYP2D6 gene are termed “poor metabolizers” and may have a decreased capacity to metabolize risperidone. These individuals may be at a higher risk of adverse effects because of increased exposure to plasma risperidone, compared to normal metabolizers, who carry two active copies of CYP2D6. Individuals who are CYP2D6 ultrarapid metabolizers (who carry more than two functional copies of CYP2D6) may have a decreased response to therapy, resulting from lower steady-state risperidone concentrations.

The FDA-approved drug label states that analysis of clinical studies involving a modest number of poor metabolizers (n=70) does not suggest that poor and extensive (normal) metabolizers have different rates of adverse effects (1). In addition, the Dutch Pharmacogenetics Working Group (DPWG) recently changed its dosing recommendations to “no action is needed” for CYP2D6 poor metabolizers taking risperidone (2).

Drug: Risperidone

Risperidone is an atypical antipsychotic primarily used in the treatment of schizophrenia and manic or mixed episodes in bipolar disorder. Risperidone may also be used as part of the management of aggression and/or psychosis in severe dementia and irritability associated with autistic disorder in children and adolescents (1).

The first antipsychotics to be discovered in the 1950s were haloperidol and chlorpromazine. Known as “first-generation” or “typical” antipsychotics, these drugs are used to treat psychosis (regardless of the underlying cause), chronic psychotic disorders (e.g., schizophrenia), and other psychiatric conditions.

All antipsychotics, with the exception of aripiprazole, are dopamine receptor antagonists. Blockade of the D2 dopamine receptor in the brain’s limbic system is thought to improve the “positive” symptoms of schizophrenia, such as delusions and hallucinations, which are signs of psychosis.

However, typical antipsychotics also block dopamine receptors in the nigrostriatal pathway. This can cause movement disorders known as extrapyramidal side effects. These disorders include akathisia (motor restlessness), dystonia (abnormal muscle tone), and tardive dyskinesia (involuntary and repetitive movements).

Newer antipsychotics, known as “second generation” or “atypical” antipsychotics, have a lower risk of extrapyramidal side effects. Risperidone is an atypical antipsychotic. The most common side effects of risperidone therapy are sedation and dry mouth, but the rates of both appear to be low, at around 5% (3). Other atypical antipsychotics approved by the FDA include aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, lurasidone, olanzapine, quetiapine, and ziprasidone.

Atypical antipsychotics, such as risperidone, are thought to transiently occupy D2 receptors and then rapidly dissociate, to allow for normal dopamine neurotransmission (4). Because risperidone has high affinity for the D2 receptor but binds it “loosely”, it does not block dopamine receptors in the nigrostriatal pathway and extrapyramidal side effects are less likely (5).

Risperidone also blocks serotonin receptors, alpha 1 adrenergic receptors, and, to a lesser extent, histamine H1 and alpha 2 adrenergic receptors.

The main route of risperidone metabolism is in the liver by the enzyme CYP2D6. The major active metabolite, 9-hydroxyrisperidone, contributes to the pharmacological effects of this drug (5). While risperidone and 9-hydroxyrisperidone are often regarded as equipotent, they display different affinities towards the two target receptors (D2 and 5HT2A), where risperidone appears to be approximately 2-fold more potent than 9-hydroxyrisperidone. There is also a difference in brain distribution; risperidone is distributed more to the CNS (6).

Genetic variations in the CYP2D6 gene may contribute to an increased risk of adverse events associated with risperidone therapy (7). Individuals who are “CYP2D6 poor metabolizers” carry two no function copies of the CYP2D6 gene. In these individuals, standard doses of risperidone may lead to increased plasma levels of risperidone and decreased levels of 9-hydoxyrisperidone.

However, it is unclear to the extent to which CYP2D6 genotype influences the efficacy and safety of risperidone therapy. One small study of 76 patients with schizophrenia reported that CYP2D6 poor metabolism was associated with greater clinical improvement in the total Positive and Negative Syndrome Scale (PANSS) (8). Other studies have reported a higher rate of adverse reactions and drug discontinuations in CYP2D6 poor metabolizers compared to normal metabolizers (5, 9, 10).

The ratio of risperidone to 9-hdroxyrisperidone, which largely reflects CYP2D6 phenotype, may be a risk factor for different side effects (11). Because prolactin levels mainly correlate with 9-hydroxyrisperidone levels, CYP2D6 ultrarapid metabolizers may experience different side effects than normal metabolizers (12). In addition, because elderly patients accumulate 9-hydroxyrisperidone due to reduced renal function, older patients who are CYP2D6 poor metabolizers (and others with reduced renal function) are at particular risk of side effects during risperidone treatment (5).

Individuals who are “CYP2D6 ultrarapid metabolizers” may have decreased plasma levels of risperidone, due to increased CYP2D6 activity—these individuals carry more than two functional copies of the CYP2D6 gene. A small study of 85 patients taking long-lasting risperidone showed that the plasma concentrations of risperidone and its active metabolite were subtherapeutic in three individuals who were CYP2D6 ultrarapid metabolizers. The study, however, did not report whether these changes affected the effectiveness or tolerability of the drug in these patients (13).

Overall, it remains unclear whether the accurate determination of an individual’s CYP2D6 genotype, together with therapeutic drug monitoring, has the potential to optimize the response of CYP2D6 poor metabolizers and ultrarapid metabolizers to antipsychotic therapy (9, 14).

The Cytochrome P450 Superfamily

The cytochrome P450 superfamily (CYP450) is a large and diverse group of enzymes that form the major system for metabolizing or detoxifying lipids, hormones, toxins, and drugs. The CYP450 genes are very polymorphic and can result in reduced, absent, or increased enzyme activity.

Gene: CYP2D6

CYP2D6 is highly polymorphic, with over 100 star (*) alleles described (15). CYP2D6*1 is the reference (or wild-type) allele encoding an enzyme with normal activity. The CYP2D6*2, *33, and *35 alleles are also considered to confer normal enzyme activity (Table 1).

Table 1.

Activity status of selected CYP2D6 alleles

Allele typeCYP2D6 Alleles
Normal function *1, *2, *33, *35
Decreased function *9, *10, *17, *29, *36, *41
No function *3, *4, *5, *6, *7, *8, *11, *12, *13, *14, *15, *16, *19, *20, *21, *38, *40, *42

For a detailed list of CYP2D6 alleles, please see (15).

Individuals who have more than two normal function copies of the CYP2D6 gene are classified as “ultrarapid metabolizers,” whereas individuals who carry two normal or one normal and one decreased function allele are classified as “normal metabolizers” (also referred to as “extensive metabolizers”).

Individuals with one normal and one no function allele or two decreased function alleles are also categorized as “normal metabolizers” by recent nomenclature guidelines (16), but have also been categorized as “intermediate metabolizers” elsewhere in the literature. Subjects with one decreased and one no function allele are predicted to be “intermediate metabolizers” and those with two no function alleles are considered to be “poor metabolizers” (Table 2).

Table 2:

2016 Assignment of CYP2D6 phenotypes by CPIC

PhenotypeActivity ScoreGenotypesExamples of diplotypes
CYP2D6 ultrarapid metabolizer
(approximately 1–20% of patients)a
Greater than 2.0An individual carrying duplications of functional alleles (*1/*1)xN
CYP2D6 normal metabolizer
(approximately 72–88% of patients)
1.0 – 2.0cAn individual carrying two normal function alleles
or two decreased function alleles
or one normal and no function allele
or one normal function and decreased function allele
or combinations of duplicated alleles that result in an activity score of 1.0 to 2.0
CYP2D6 intermediate metabolizer
(approximately 1–13% of patients)
0.5An individual carrying one decreased function and one no function allele *4/*41
CYP2D6 poor metabolizer
(approximately 1–10% of patients)
0An individual carrying two no function alleles *4/*4

For population-specific allele and phenotype frequencies, please see (17).
b Where xN represents the number of CYP2D6 gene copies (N is 2 or more).


Patients with an activity core of 1.0 may be classified as intermediate metabolizers by some reference laboratories.

For more information about activity scores, please see the Genetic Testing section.

This table has been adapted from Hicks J.K., Sangkuhl K., Swen J.J., Ellingrod V.L., Müller D.J., Shimoda K., Bishop J.R., Kharasch E.D., Skaar T.C., Gaedigk A., Dunnenberger H.M., Klein T.E., Caudle K.E. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update. Clinical pharmacology and therapeutics. 2016 Dec 20 [Epub ahead of print] (17).

The most common no function alleles include CYP2D6*3, *4, *5, and *6 (18, 19, 20, 21), and the most common decreased function alleles include CYP2D6*9, *10, *17, *29 and *41 (19, 21, 22, 23, 24). There are large inter-ethnic differences in the frequency of these alleles. For example, CYP2D6*4 is the most common no function allele in Caucasians, but is less abundant in subjects with African ancestry and is rare in Asians. In contrast, the decreased function allele CYP2D6*10 is the most common allele in Asians, and CYP2D6*17 is almost exclusively found in individuals with African ancestry (25).

Consequently, the phenotype frequencies also vary substantially among the major ethnicities and may vary among populations. Approximately 6–10% of European Caucasians and their descendants are poor metabolizers, mainly due to the prevalent no function CYP2D6*4 and *5 alleles (26, 27).

Genetic Testing

The NIH’s Genetic Testing Registry provides examples of the genetic tests that are currently available for risperidone response and for the CYP2D6 gene.

Results are typically reported as a diplotype, such as CYP2D6 *1/*1. A result for copy number, if available, is also important when interpreting CYP2D6 genotyping results (28). However, it is important to note that the number of variants tested can vary among laboratories, which can result in diplotype result discrepancies between testing platforms and laboratories (29).

If the test results include an interpretation of the patient’s predicted metabolizer phenotype, this should be confirmed by checking the diplotype and assigning an activity score to each allele (e.g., 0 for no function, 0.5 for decreased function, and 1 for each copy of a normal function allele). The phenotype is defined by the sum of the two scores:

  • A normal (previously referred to as “extensive”) metabolizer phenotype has an activity score of 1 to 2
  • An intermediate metabolizer has an activity score of 0.5
  • A poor metabolizer has an activity score of 0
  • An ultrarapid metabolizer has an activity score greater than 2 (17, 30)

Therapeutic Recommendations based on Genotype

This section contains excerpted1 information on gene-based dosing recommendations. Neither this section nor other parts of this review contain the complete recommendations from the sources.

2016 Statement from the US Food and Drug Administration (FDA): Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.

CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP 2D6 is subject to genetic polymorphism (about 6%–8% of Caucasians, and a very low percentage of Asians, have little or no activity and are "poor metabolizers") and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive2 CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.

Please review the complete therapeutic recommendations that are located here: (1).

2017 Summary of recommendations from the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Association for the Advancement of Pharmacy (KNMP):

CYP2D6 Poor metabolizers:

No action is needed for this gene-drug interaction.

The genetic variation can result in both an increase in side effects and a stronger decrease in schizophrenia symptoms. In addition to this, the genetic variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.

CYP2D6 intermediate metabolizers:

No action is needed for this gene-drug interaction.

There is little evidence to support an increase in side effects caused by the genetic variation. The genetic variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.

CYP2D6 ultrarapid metabolizers:

No action is needed for this gene-drug interaction.

Genetic variation may lead to an increase in the required maintenance dose. However, as the effect is smaller than that of the normal biological variation, action is not useful.

Please review the complete therapeutic recommendations that are located here: (2).


Nomenclature for selected CYP2D6 alleles

Common allele nameAlternative names / Major SNPHGVS reference sequencedbSNP reference identifier for allele location
CYP2D6*4 1846G>A NM_000106.5:c.506-1G>A Not applicable - variant occurs in a non-coding region rs3892097
CYP2D6*5 Not applicable - variant results in a whole gene deletion
CYP2D6*6 1707 del T Trp152Gly NM_000106.5:c.454delT NP_000097.3:p.Trp152Glyfs rs5030655
CYP2D6*10 100C>T Pro34Ser NM_000106.5:c.100C>T NP_000097.3:p.Pro34Ser rs1065852
CYP2D6*17 Includes at least two functional variants*:
1023C>T (Thr107Ile)
2850C>T (Cys296Arg)
rs28371706 rs16947
CYP2D6*41 2988G>ANM_000106.5:c.985+39G>ANot applicable – variant occurs in a non-coding region rs28371725

SNP= Single Nucleotide Polymorphism
*In the literature, 1023C>T is also referred to as 1111C>T, and 2850C>T is also referred to 2938C>T.

Guidelines for the description and nomenclature of gene variations are available from the Human Genome Variation Society (HGVS): http://www.hgvs.org/content/guidelines

Nomenclature for Cytochrome P450 enzymes is available from the Pharmacogene Variation Consortium (PharmVar) https://www.pharmvar.org/.


The author would like to thank the following individuals for reviewing this summary:

John T. Callaghan, M.D., Ph.D., Associate Dean of Veterans Affairs Research, Associate Professor of Medicine, and Adjunct Associate Professor of Pharmacology and Toxicology, Department of Veterans Affairs, and Indiana University School of Medicine; Houda Hachad, PharmD, M.Res, Chief Science Officer, Translational Software, Seattle, WA; Ben Kong, PharmD, BCPS, Clinical Pharmacist, Oregon Health & Science University; Mark W. Linder, Ph.D., Professor, and Assistant Director, Clinical Chemistry and Toxicology, University of Louisville Hospital, and Associate Director, Pharmacogenetics Diagnostic Laboratory, Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine; Espen Molden, Ph.D., Research Leader, Diakonhjemmet Hospital, and Professor, University of Oslo, Norway; Mohamed Nagy, RPh, MSc, Clinical Pharmacist, Head of the Personalised Medication Management Unit, Department of Pharmaceutical Services, Children's Cancer Hospital, Egypt; George P. Patrinos, Ph.D., Associate Professor, University of Patras School of Health Sciences, Greece; Mandy van Rhenen, MSc, Secretary, Dutch Pharmacogenetics Working Group (DPWG), Centre for Information on Medicines, Royal Dutch Pharmacists Association (KNMP); Chonlaphat Sukasem, B. Pharm, Ph.D, Associate Professor and Head, Division of Pharmacogenomics and Personalized Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.



RISPERDAL CONSTA- risperidone [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals, I.; 2016. Available from: https://dailymed​.nlm​.nih.gov/dailymed/drugInfo​.cfm?setid=bb34ee82-d2c2-43b8-ba21-2825c0954691


Royal Dutch Pharmacists Association (KNMP). Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Guidelines [Internet]. Netherlands. Risperidone – CYP2D6 [Cited March 2017]. Available from: http://kennisbank​.knmp.nl [Access is restricted to KNMP membership.]


Mahmoud, R.A., G.J. Pandina, I. Turkoz, C. Kosik-Gonzalez, et al., Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med, 2007. 147(9): p. 593-602.


Seeman, P., Atypical antipsychotics: mechanism of action. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002. 47(1): p. 27-38.


Molden, E., R.B. Waade, M. Hoff and T. Haslemo, Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. Basic Clin Pharmacol Toxicol, 2016. 119(5): p. 470-475.


Hendset, M., T. Haslemo, I. Rudberg, H. Refsum, et al., The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry, 2006. 39(4): p. 121-7.


de Leon, J., M.T. Susce, R.M. Pan, M. Fairchild, et al., The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry, 2005. 66(1): p. 15-27.


Almoguera, B., R. Riveiro-Alvarez, J. Lopez-Castroman, P. Dorado, et al., CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics, 2013. 23(11): p. 627-30.


Lisbeth, P., H. Vincent, M. Kristof, S. Bernard, et al., Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol, 2016. 72(2): p. 175-84.


Patteet, L., V. Haufroid, K. Maudens, B. Sabbe, et al., Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol, 2016.


Cartwright, A.L., K.J. Wilby, S. Corrigan and M.H. Ensom, Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother, 2013. 47(3): p. 350-60.


Knegtering, R., P. Baselmans, S. Castelein, F. Bosker, et al., Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry, 2005. 162(5): p. 1010-2.


Ganoci, L., M. Lovric, M. Zivkovic, M. Sagud, et al., The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone. Clin Ther, 2016. 38(10S): p. e10-e11.


Vanwong, N., N. Ngamsamut, Y. Hongkaew, N. Nuntamool, et al., Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metab Pharmacokinet, 2016. 31(2): p. 156-62.


The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Internet]. PharmVar [Cited Dember 14, December 2015]. Available from: https://www​.pharmvar.org/


Caudle, K.E., H.M. Dunnenberger, R.R. Freimuth, J.F. Peterson, et al., Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med, 2016.


Kevin Hicks, J., K. Sangkuhl, J.J. Swen, V.L. Ellingrod, et al., Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC(R)) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update. Clin Pharmacol Ther, 2016.


Mayo Clinic Mayo Medical Laboratories. Test ID: AMTRP: Amitriptyline and Nortriptyline, Serum. Mayo Clinic Mayo Medical Laboratories 19 August 2016; Available from: http://www​.mayomedicallaboratories​.com/test-catalog​/Clinical+and+Interpretive​/63506.


de Vos, A., J. van der Weide and H.M. Loovers, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J, 2011. 11(5): p. 359-67.


Ulrich, S. and J. Lauter, Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet, 2002. 41(11): p. 853-76.


Steimer, W., K. Zopf, S. von Amelunxen, H. Pfeiffer, et al., Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem, 2005. 51(2): p. 376-85.


van der Weide, J., E.H. van Baalen-Benedek and J.E. Kootstra-Ros, Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit, 2005. 27(4): p. 478-83.


Stern, S.L., H.S. Ribner, T.B. Cooper, L.D. Nelson, et al., 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults. J Clin Psychopharmacol, 1991. 11(2): p. 93-8.


Schneider, L.S., T.B. Cooper, J.A. Severson, T. Zemplenyi, et al., Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol, 1988. 8(6): p. 402-8.


Gaedigk, A., K. Sangkuhl, M. Whirl-Carrillo, T. Klein, et al., Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med, 2016.


Bradford, L.D., CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 2002. 3(2): p. 229-43.


Lerena, L.A., M.E. Naranjo, F. Rodrigues-Soares, L.E.M. Penas, et al., Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol, 2014. 10(11): p. 1569-83.


Hicks, J.K., J.R. Bishop, K. Sangkuhl, D.J. Muller, et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther, 2015. 98(2): p. 127-34.


Hicks, J.K., J.J. Swen and A. Gaedigk, Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab, 2014. 15(2): p. 218-32.


Gaedigk, A., S.D. Simon, R.E. Pearce, L.D. Bradford, et al., The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther, 2008. 83(2): p. 234-42.



The FDA labels specific drug formulations. We have substituted the generic names for any drug labels in this excerpt. The FDA may not have labeled all formulations containing the generic drug.


The FDA statement uses the term “extensive metabolizer.” CPIC recently introduced standardized nomenclature for pharmacogenetic terms, which included replacing the term “extensive metabolizer” with the term “normal metabolizer.” More details can be found in the 2016 paper, “Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)” 16. Caudle, K.E., H.M. Dunnenberger, R.R. Freimuth, J.F. Peterson, et al., Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med, 2016.

Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

Bookshelf ID: NBK425795PMID: 28520384


Tests in GTR by Condition

Tests in GTR by Gene

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...